Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 17/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.68 |
| ▸ | SRC | P12931 | 10/20 | 0.68 |
| ▸ | SYK | P43405 | 10/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16106395 | 0.89 | GSK3A (0.69) | GSK3AMAPK14SRCSYKCYP3A4 | |
| SCHEMBL1936288 | 0.86 | GSK3A (0.54) | GSK3AMAPK14SRCSYKCYP3A4 | |
| SCHEMBL1936773 | 0.82 | BRAF (0.51) | GSK3AMAPK14SRCSYKCYP3A4 | |
| SCHEMBL1934475 | 0.82 | BRAF (0.56) | GSK3AMAPK14SRCSYK | |
| SCHEMBL16106269 | 0.81 | GSK3A (1.00) | GSK3AMAPK14SRCSYKCYP3A4 | |
| SCHEMBL23967439 | 0.81 | GSK3A (0.67) | GSK3AMAPK14SRCSYKCYP3A4 | |
| SCHEMBL1935949 | 0.81 | GSK3A (0.49) | GSK3AMAPK14SRCSYKCYP3A4 | |
| SCHEMBL4084225 | 0.81 | MAPK14 (0.49) | GSK3AMAPK14SRCSYKCYP3A4 | |
| SCHEMBL6300965 | 0.81 | GSK3A (0.67) | GSK3AMAPK14SRCSYKCYP3A4 | |
| SCHEMBL16138970 | 0.81 | GSK3A (0.67) | GSK3AMAPK14SRCSYKCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981535-B1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | TOPIVERT PHARMA LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-10435361-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| US-20180044288-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-9790174-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-20160376232-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-12-29 | — | — | US | disclosed |
| US-9481648-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2016-11-01 | — | — | US | disclosed |
| US-20150166483-A1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20140296208-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044288-A1 | KINASE INHIBITORS | SYK, LYN, BTK | GSK3A 231/4885MAPK14 121/4885SRC 4/4885 |
| US-20160376232-A1 | KINASE INHIBITORS | LYN, SYK, LCK | GSK3A 907/4885MAPK14 53/4885SRC 6/4885 |
| US-20150166483-A1 | KINASE INHIBITORS | LCK, SYK, FYN | GSK3A 419/4885MAPK14 42/4885SRC 4/4885 |
| US-10435361-B2 | Kinase inhibitors | SYK, LYN, BTK | GSK3A 231/4885MAPK14 121/4885SRC 4/4885 |
| US-20140296208-A1 | KINASE INHIBITORS | SYK, LYN, BTK | GSK3A 231/4885MAPK14 121/4885SRC 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.